The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights

Autor(es)

Lazarini-Lopes, Willian ^{[1, 2]} ; Do Val-da Silva, Raquel A. ^[1] ; da Silva-Junior, Rui M. P. ^[2] ; Leite, Joao P. ^[1] ; Garcia-Cairasco, Norberto ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Ribeirao Preto Sch Med, Neurosci & Behav Sci Dept, Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Ribeirao Preto Sch Med, Physiol Dept, Neurophysiol & Expt Neuroethol Lab, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS; v. 111, p. 166-182, APR 2020.
• Citações Web of Science: 0

Resumo

Epilepsy is a neurological disorder characterized by the presence of seizures and neuropsychiatric comorbidities. Despite the number of antiepileptic drugs, one-third of patients did not have their seizures under control, leading to pharmacoresistance epilepsy. Cannabis sativa has been used since ancient times in Medicine for the treatment of many diseases, including convulsive seizures. In this context, Cannabidiol (CBD), a non-psychoactive phytocannabinoid present in Cannabis, has been a promising compound for treating epilepsies due to its anticonvulsant properties in animal models and humans, especially in pharmacoresistant patients. In this review, we summarize evidence of the CBD anticonvulsant activities present in a great diversity of animal models. Special attention was given to behavioral CBD effects and its translation to human epilepsies. CBD anticonvulsant effects are associated with a great variety of mechanisms of action such as endocannabinoid and calcium signaling. CBD has shown effectiveness in the clinical scenario for epilepsies, but its effects on epilepsy-related comorbidities are scarce even in basic research. More detailed and complex behavioral evaluation about CBD effects on seizures and epilepsy-related comorbidities are required. (AU)

• Processo FAPESP: 19/05957-8 - Epilepsias e comorbidades neuropsiquiátricas: caracterização dos efeitos do tratamento com canabidiol e huf-101 em modelos experimentais in vivo e in vitro
• Beneficiário: Norberto Garcia Cairasco
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/50891-1 - INCT 2014: Translacional em Medicina
• Beneficiário: Jaime Eduardo Cecilio Hallak
• Linha de fomento: Auxílio à Pesquisa - Temático
• Processo FAPESP: 19/00849-2 - "mecanismos fisiopatológicos e moleculares de tumorigênese: abordagem baseada em plataformas de sequenciamento em escala genômica (NGS - Next-Generation Sequencing)"
• Beneficiário: Rui Milton Patrício da Silva Junior
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado